Although detailed molecular mechanisms by which cytoplasmic maspin activates SRGN/TGFβ2 axis remain to be clarified, our data suggest that cytoplasmic maspin plays a pivotal role in the aggressive phenotype and serves as a therapeutic target in patients with breast cancer, especially TNBC. Here, SRGN is linked to breast cancer.